Joseph La Barge, J.D.

    Joe La Barge
    Joseph La Barge, J.D.
    Chief Legal Officer
    Joe La Barge is a seasoned executive and legal advisor with more than 15 years of experience counseling life science companies and healthcare institutions. Before joining Spark Therapeutics, Joe was vice president, general counsel and chief compliance officer at Tengion, Inc., a clinical-stage regenerative medicine company, where he oversaw legal affairs, compliance and quality assurance. While at Tengion, Joe helped lead the company’s initial public offering in 2010. Joe also played an integral role in developing Tengion’s intellectual property strategies for their novel, first-in-class, cell-based therapies.

    Joe was previously of counsel at Ballard Spahr LLP in Philadelphia, where he advised biotechnology companies in private and public financings, mergers and acquisitions, and collaboration and licensing transactions. He also served as deputy general counsel to the Kennedy Health System in New Jersey.

    Joe received his J.D. from Temple University and a B.A. from Bucknell University.

    Steven Altschuler

    Steven Altschuler
    Steven M. Altschuler M.D.
    Senior Vice President of Health Affairs, University of Miami CEO, UHealth-University of Miami Health System

    Dr. Steven M. Altschuler, is Senior Vice President of Health Affairs at the University of Miami and Chief Executive Officer of UHealth-University of Miami Health System. He was named to the position in November 2015.

    Steve is responsible for the strategic and operational leadership of the University’s clinical delivery system, which includes the University’s hospitals, faculty practice plan and clinics. As South Florida’s only academic-based health system, UHealth combines patient care, research and education to create a leading-edge, precision medicine approach to health care. UHealth’s comprehensive network includes three hospitals: Sylvester Comprehensive Cancer Center, the only Cancer Center of Excellence in South Florida, as designated by the state; University of Miami Hospital, the flagship hospital of UHealth; and Bascom Palmer Eye Institute, which has been recognized as the nation’s No. 1 eye hospital for 12 years in a row by U.S. News & World Report.

    In addition, UHealth has more than a dozen outpatient facilities in Miami-Dade, Broward, Palm Beach and Collier counties; a new Bascom Palmer eye clinic in Naples, on Florida’s Gulf Coast; and a 200,000-square-foot ambulatory care facility, currently under construction, that will open on the University’s Coral Gables main campus in late 2016.

    Previously, Steve was the CEO of The Children’s Hospital of Philadelphia (CHOP), the nation’s oldest hospital dedicated to the care of sick children. Children’s Hospital’s Board of Trustees elected him to his position in April 2000, after an intensive international search. Prior to assuming this role, he was the Physician-in-Chief and the first holder of the Leonard and Madlyn Abramson Endowed Chair in Pediatrics at The Children’s Hospital of Philadelphia, and professor and chair of the Department of Pediatrics at the University of Pennsylvania School of Medicine. Dr. Altschuler took the reins of the now 527-bed hospital, at the initiation of the greatest period of growth in the institution’s 159-year history. CHOP has been ranked the nation’s No. 1 or 2 children’s hospital since 2000 by U.S. News & World Report.

    Steve received his B.A. in mathematics and his M.D. from Case Western Reserve University in Cleveland, Ohio. His pediatric internship and residency were taken at Children’s Hospital Medical Center-Boston, and he completed fellowship training in Gastroenterology and Nutrition at The Children’s Hospital of Philadelphia and the University of Pennsylvania School of Medicine. From 1985 to 2000, he was a faculty member of the Department of Pediatrics at the University of Pennsylvania School of Medicine. His academic interests were focused in the area of gastrointestinal motility and included the leadership of a large clinical program, an NIH-funded research laboratory and a fellowship training program. He is a frequent guest lecturer locally, nationally and internationally.

    Currently, Steve serves on the boards of Mead Johnson Nutritionals, Weight Watchers and Spark Therapeutics.

    Independent Director

    John Furey

      jhon furey photo
      John Furey
      Chief Operating Officer
      John Furey is responsible for global commercial operations, medical affairs, technology development and technical operations at Spark Therapeutics. He has 25 years of experience in developing and implementing operational strategies and leading commercial and technical teams.

      Prior to joining Spark Therapeutics, John was senior vice president and head of global operations for Baxalta, where he directed manufacturing, quality, engineering, and process development. He actively managed a $2.5 billion production budget across Baxalta's global network and led a first-in-class supply chain organization for rare diseases. John led the team that coordinated and delivered the successful establishment of Baxalta through a spin out from Baxter and led the Baxter Vaccine inline business to realize significant top line and bottom line growth. He also spent two years in China as general manager of Pfizer’s vaccine business unit following a role with responsibility for global pricing and reimbursement at Pfizer Vaccines. In these roles, John gained extensive experience in pipeline development and global product launches. Earlier in his career, he held both commercial and operations positions of increasing scope and responsibility with Pfizer and Wyeth Pharmaceuticals.

      John has an executive M.B.A. from St. Joseph’s University, Philadelphia, a B.S. from Trinity College, Dublin, and a diploma in Environmental Health from the Dublin Institute of Technology.

      Daniel R. Faga

        Dan faga photo
        Daniel R. Faga
        Chief Business Officer
        Dan Faga brings more than 15 years of biopharma industry experience to the company. Dan is responsible for Corporate Strategy & Public Affairs at Spark Therapeutics including leadership of the portfolio and new product planning, patient advocacy, business development, alliance management, corporate communications and corporate strategy functions.

        Prior to joining Spark Therapeutics, Dan was a managing director at Centerview Partners, where he served as a founding member of Centerview’s healthcare advisory practice. Primarily focused in the life sciences sector, Dan has extensive expertise in corporate strategy, mergers and acquisitions, and partnering, and he has advised on more than $50 billion in biopharma transactions. Prior to Centerview, Dan worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the life sciences practice at PRTM.

        Dan earned a B.S. in engineering from Cornell University and an M.B.A. in healthcare management from the Wharton School of the University of Pennsylvania.